☆ 4.7 Article

Charge reversal yolk-shell liposome co-loaded JQ1 and doxorubicin with high drug loading and optimal ratio for synergistically enhanced tumor chemo-immunotherapy via blockade PD-L1 pathway

INTERNATIONAL JOURNAL OF PHARMACEUTICS (2023)

Related references

Note: Only part of the references are listed.

Article Chemistry, Multidisciplinary

Micellar paclitaxel boosts ICD and chemo-immunotherapy of metastatic triple negative breast cancer

Xinyun Qiu et al.

Summary: ATN-MPTX, constructed with the clinically validated ATN peptide as a ligand and reduction-sensitive biodegradable micelles as a vehicle, demonstrates strong and selective induction of ICD and chemo-immunotherapy for TNBC, showing superior tumor accumulation and treatment efficacy compared to controls in therapeutic studies.

JOURNAL OF CONTROLLED RELEASE (2022)

Add to Collection

Article Oncology

BRD4-IRF1 axis regulates chemoradiotherapy-induced PD-L1 expression and immune evasion in non-small cell lung cancer

Jian Wang et al.

Summary: The study showed that targeting BRD4 synergized with chemoradiotherapy and anti-PD-1 antibody to enhance anti-tumour immunity in NSCLC. BRD4 inhibitors JQ1 and ARV-771 were identified to suppress cisplatin and radiation-induced PD-L1 expression. Disrupting recruitment of BRD4-IRF1 complex to PD-L1 promoter was proposed as the mechanism of BRD4 inhibition on chemoradiation-induced PD-L1 expression. In vivo experiments demonstrated that BRD4 inhibition combined with chemoradiotherapy and PD-1 blockade resulted in a robust anti-tumour immunity without increased toxicities.

CLINICAL AND TRANSLATIONAL MEDICINE (2022)

Add to Collection

Review Oncology

Biological causes of immunogenic cancer cell death (ICD) and anti-tumor therapy; Combination of Oncolytic virus-based immunotherapy and CAR T-cell therapy for ICD induction

Amirhossein Mardi et al.

Summary: CAR T-cell therapy has shown progress in hematologic malignancies but faces challenges in solid tumors. Combining oncolytic virotherapy with CAR T-cells may be a promising strategy to overcome these obstacles.

CANCER CELL INTERNATIONAL (2022)

Add to Collection

Article Chemistry, Multidisciplinary

A bio-responsive, cargo-catchable gel for postsurgical tumor treatment via ICD-based immunotherapy

Qian Chen et al.

Summary: This study presents a strategy utilizing immunogenic cell death (ICD) to stimulate anti-tumor adaptive immune response, combined with a bio-responsive and cargo-catchable gel depot for drug delivery, to prevent tumor recurrence and metastasis after surgery.

JOURNAL OF CONTROLLED RELEASE (2022)

Add to Collection

Article Pharmacology & Pharmacy

Stability characterization for pharmaceutical liposome product development with focus on regulatory considerations: An update

Vaskuri G. S. Sainaga Jyothi et al.

Summary: Liposomes have advantages as drug carriers, but their stability is a major concern. This review examines the instabilities encountered during liposomal formulation development and discusses ways to overcome them, including strategies for dealing with microbiological contamination and quality control techniques recommended by regulatory agencies.

INTERNATIONAL JOURNAL OF PHARMACEUTICS (2022)

Add to Collection

Article Chemistry, Multidisciplinary

Anti-PD-L1 mediating tumor-targeted codelivery of liposomal irinotecan/JQ1 for chemo-immunotherapy

Zhi-di He et al.

Summary: The development of a PD-L1-targeting immune liposome for co-delivering irinotecan and JQ1 enhances antitumor immunity in colorectal cancer by inducing immunogenic cell death and interfering in the immunosuppressive pathway, leading to increased intratumoral drug accumulation, DC maturation, adaptive immune responses, and remodeled tumor immune microenvironment. This chemo-immunotherapy strategy effectively activates the host immune system and inhibits tumor growth.

ACTA PHARMACOLOGICA SINICA (2021)

Add to Collection

Review Oncology

Regulation of PD-L1 expression in the tumor microenvironment

Ming Yi et al.

Summary: PD-L1 expression is regulated by various factors, impacting the treatment effect and patient selection. Understanding the mechanisms of PD-L1 regulation helps enhance the efficacy of immunotherapy.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)

Add to Collection

Article Chemistry, Multidisciplinary

Overcoming immune resistance by sequential prodrug nanovesicles for promoting chemoimmunotherapy of cancer

Fengqi Zhou et al.

Summary: The study introduces a sequential prodrug nanovesicle designed to enhance drug delivery to tumor tissues and reduce immunological resistance of tumor cells. The nanovesicles show promising results in inhibiting tumor growth and suppressing metastasis in mouse models, providing a new approach for chemoimmunotherapy of cancers by overcoming immune evasion through the IFN-gamma-BRD4-PD-L1 axis.

NANO TODAY (2021)

Add to Collection

Review Oncology

Achieving clinical success with BET inhibitors as anti-cancer agents

Tatiana Shorstova et al.

Summary: Transcriptional upregulation of oncogenes drives tumor progression, and targeting BET proteins with inhibitors has shown promise in suppressing oncogenic networks in tumors. Understanding the biology of BET proteins, designing better BET inhibitors, and incorporating BET inhibitors into combination therapies can enhance their efficacy in clinical settings.

BRITISH JOURNAL OF CANCER (2021)

Add to Collection

Review Pharmacology & Pharmacy

Design of liposomes as drug delivery system for therapeutic applications

Diana Guimaraes et al.

Summary: Liposomes are effective drug delivery systems that improve therapeutic efficacy, being nontoxic and biodegradable. Key aspects such as design, production techniques, drug loading, and characterization for in vitro and in vivo performance are essential for successful liposomal formulations. Other topics explored include functionalization, targeting strategies, stability, limitations, and current market applications of liposomes in various therapeutic fields.

INTERNATIONAL JOURNAL OF PHARMACEUTICS (2021)

Add to Collection

Review Pharmacology & Pharmacy

PLGA-based nanomedicines manufacturing: Technologies overview and challenges in industrial scale-up

Maria Camilla Operti et al.

Summary: Nanomedicines based on PLGA carriers show great potential for biomedical research, but are not yet available on the global market. Challenges include scaling up production and successful translation into clinical practice, requiring advancements in manufacturing techniques and quality control methods.

INTERNATIONAL JOURNAL OF PHARMACEUTICS (2021)

Add to Collection

Article Multidisciplinary Sciences

Molecular determinants of response to PD-L1 blockade across tumor types

Romain Banchereau et al.

Summary: This study used immunohistochemistry, tumor mutation burden, and RNA-seq data to identify molecular signatures of response to PD-L1 immune checkpoint inhibition across different indications such as NSCLC, UC, and RCC. The results revealed pathway heterogeneity and the involvement of non-immune pathways in the response to checkpoint blockade, highlighting the importance of indication-specific molecular approaches in formulating treatment strategies.

NATURE COMMUNICATIONS (2021)

Add to Collection

Article Oncology

Effect of Postoperative Radiotherapy for Patients With pIIIA-N2 Non-Small Cell Lung Cancer After Complete Resection and Adjuvant Chemotherapy The Phase 3 PORT-C Randomized Clinical Trial

Zhouguang Hui et al.

Summary: The study evaluated the impact of postoperative radiotherapy (PORT) on survival and safety in patients with pIIIA-N2 non-small cell lung cancer. The results showed that PORT did not improve disease-free survival but helped reduce local recurrence.

JAMA ONCOLOGY (2021)

Add to Collection

Article Surgery

Survival in Locally Advanced Pancreatic Cancer After Neoadjuvant Therapy and Surgical Resection

Georgios Gemenetzis et al.

ANNALS OF SURGERY (2019)

Add to Collection

Review Biochemistry & Molecular Biology

The influence of microenvironment on tumor immunotherapy

Jieying Zhang et al.

FEBS JOURNAL (2019)

Add to Collection

Article Multidisciplinary Sciences

Immunostimulatory nanomedicines synergize with checkpoint blockade immunotherapy to eradicate colorectal tumors

Xiaopin Duan et al.

NATURE COMMUNICATIONS (2019)

Add to Collection

Article Oncology

IFN-gamma-induced PD-L1 expression in melanoma depends on p53 expression

Alexander Thiem et al.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)

Add to Collection

Article Chemistry, Multidisciplinary

Redox-Activated Porphyrin-Based Liposome Remote-Loaded with Indoleamine 2,3-Dioxygenase (IDO) Inhibitor for Synergistic Photoimmunotherapy through Induction of Immunogenic Cell Death and Blockage of IDO Pathway

Dechun Liu et al.

NANO LETTERS (2019)

Add to Collection

Article Nanoscience & Nanotechnology

Smart cancer nanomedicine

Roy van der Meel et al.

NATURE NANOTECHNOLOGY (2019)

Add to Collection

Article Chemistry, Multidisciplinary

In Situ Dendritic Cell Vaccine for Effective Cancer Immunotherapy

Weijing Yang et al.

ACS NANO (2019)

Add to Collection

Article Multidisciplinary Sciences

Elimination of established tumors with nanodisc-based combination chemoimmunotherapy

Rui Kuai et al.

SCIENCE ADVANCES (2018)

Add to Collection

Article Multidisciplinary Sciences

Cancer cells with trapped nuclei cut their way through the extracellular matrix

Emmanuel Dornier et al.

NATURE COMMUNICATIONS (2018)

Add to Collection

Article Cell Biology

BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1

Simon J. Hogg et al.

CELL REPORTS (2017)

Add to Collection

Article Engineering, Biomedical

Inducing enhanced immunogenic cell death with nanocarrier-based drug delivery systems for pancreatic cancer therapy

Xiao Zhao et al.

BIOMATERIALS (2016)

Add to Collection

Review Immunology

IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance

David H. Munn et al.

TRENDS IN IMMUNOLOGY (2016)

Add to Collection

Article Cell Biology

BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression

Hengrui Zhu et al.

CELL REPORTS (2016)

Add to Collection

Article Multidisciplinary Sciences

Nanoparticle biointerfacing by platelet membrane cloaking

Che-Ming J. Hu et al.

NATURE (2015)

Add to Collection

Article Chemistry, Multidisciplinary

Platelet-like Nanoparticles: Mimicking Shape, Flexibility, and Surface Biology of Platelets To Target Vascular Injuries

Aaron C. Anselmo et al.

ACS NANO (2014)

Add to Collection

Article Chemistry, Multidisciplinary

Nanoparticles with Precise Ratiometric Co-Loading and Co-Delivery of Gemcitabine Monophosphate and Cisplatin for Treatment of Bladder Cancer

Lei Miao et al.

ADVANCED FUNCTIONAL MATERIALS (2014)

Add to Collection

Editorial Material Medicine, General & Internal

Tumor Immunotherapy Directed at PD-1

Antoni Ribas

NEW ENGLAND JOURNAL OF MEDICINE (2012)

Add to Collection

Review Oncology

Immunogenic cell death and DAMPs in cancer therapy

Dmitri V. Krysko et al.

NATURE REVIEWS CANCER (2012)

Add to Collection

Article Multidisciplinary Sciences

Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform

Che-Ming J. Hu et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)

Add to Collection

Review Biotechnology & Applied Microbiology

Nanoparticle therapeutics: an emerging treatment modality for cancer

Mark E. Davis et al.

NATURE REVIEWS DRUG DISCOVERY (2008)

Add to Collection

© Peeref 2019-2024. All rights reserved.